MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
November 05 2021 - 11:54AM
Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostics company specializing in the early
detection of cancer, announces that its shares have commenced
trading today on the Nasdaq Capital Market under the ticker symbol
“MYNZ”.
On November 4, 2021, the Company priced its firm commitment
underwritten public offering (the "Offering") of 2,000,000 common
shares at a public offering price of $5.00 per share. The gross
proceeds to the Company from the Offering will be $10,000,000,
before deducting underwriting discounts, commissions and other
expenses.
The Offering is expected to close on or about November 9, 2021,
subject to customary closing conditions.
The securities described above are being sold by Mainz Biomed
N.V. pursuant to a registration statement, as amended, filed by the
Company with the Securities and Exchange Commission (the "SEC"),
which was declared effective on November 4, 2021. The Offering has
been made only by means of a prospectus. A copy of the final
prospectus related to the Offering may be obtained, when available,
from Boustead Securities, LLC, via email:
offerings@boustead1828.com or by calling +1 (949) 502-4408 or
standard mail at Boustead Securities, LLC, Attn: Equity Capital
Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition,
a copy of the final prospectus relating to the Offering may be
obtained via the SEC's website at www.sec.gov.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic
solutions for life-threatening conditions. The Company's flagship
product is ColoAlert, an accurate, non-invasive, and easy-to-use
early detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed across Europe with FDA clinical study and
submission process intended to be launched in the first half of
2022 for U.S. regulatory approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information please visit
www.mainzbiomed.com
For media enquiries, please contact
press@mainzbiomed.com
For investor enquiries, please contact
ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as “anticipate”, “believe”, “expect”, “estimate”,
“plan”, “outlook”, and “project” and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
reflect the current analysis of existing information and are
subject to various risks and uncertainties. As a result, caution
must be exercised in relying on forward-looking statements. Due to
known and unknown risks, actual results may differ materially from
the Company’s expectations or projections. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: (i) the
failure to meet projected development and related targets; (ii)
changes in applicable laws or regulations; (iii) the effect of the
COVID-19 pandemic on the Company and its current or intended
markets; and (iv) other risks and uncertainties described herein,
as well as those risks and uncertainties discussed from time to
time in other reports and other public filings with the Securities
and Exchange Commission (the “SEC”) by the Company. Additional
information concerning these and other factors that may impact the
Company’s expectations and projections can be found in its initial
filings with the SEC, including its Prospectus filed on October 12,
2021 and amended on October 25, 2021 and November 1, 2021. The
Company’s SEC filings are available publicly on the SEC's website
at www.sec.gov. Any forward-looking statement made by us in this
press release is based only on information currently available to
Mainz Biomed and speaks only as of the date on which it is made.
Mainz Biomed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024